ASCO 2023: Targeted Therapy for Early-Stage NSCLC

Bibliographic Details
Main Author: Roy Herbst
Format: Article
Language:English
Published: THE HEALTHBOOK COMPANY LTD. 2023-06-01
Series:healthbook TIMES. Oncology Hematology
Online Access:https://doi.org/10.36000/hbT.OH.2023.16.113
_version_ 1797341563871821824
author Roy Herbst
author_facet Roy Herbst
author_sort Roy Herbst
collection DOAJ
first_indexed 2024-03-08T10:20:01Z
format Article
id doaj.art-abda95a0f2574e589dcb00c6c7879bea
institution Directory Open Access Journal
issn 2673-2092
2673-2106
language English
last_indexed 2024-03-08T10:20:01Z
publishDate 2023-06-01
publisher THE HEALTHBOOK COMPANY LTD.
record_format Article
series healthbook TIMES. Oncology Hematology
spelling doaj.art-abda95a0f2574e589dcb00c6c7879bea2024-01-28T00:46:17ZengTHE HEALTHBOOK COMPANY LTD.healthbook TIMES. Oncology Hematology2673-20922673-21062023-06-01162ASCO 2023: Targeted Therapy for Early-Stage NSCLCRoy Herbsthttps://doi.org/10.36000/hbT.OH.2023.16.113
spellingShingle Roy Herbst
ASCO 2023: Targeted Therapy for Early-Stage NSCLC
healthbook TIMES. Oncology Hematology
title ASCO 2023: Targeted Therapy for Early-Stage NSCLC
title_full ASCO 2023: Targeted Therapy for Early-Stage NSCLC
title_fullStr ASCO 2023: Targeted Therapy for Early-Stage NSCLC
title_full_unstemmed ASCO 2023: Targeted Therapy for Early-Stage NSCLC
title_short ASCO 2023: Targeted Therapy for Early-Stage NSCLC
title_sort asco 2023 targeted therapy for early stage nsclc
url https://doi.org/10.36000/hbT.OH.2023.16.113
work_keys_str_mv AT royherbst asco2023targetedtherapyforearlystagensclc